Prolactinoma medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 8: | Line 8: | ||
==Medical Therapy== | ==Medical Therapy== | ||
Medical therapy for prolactinoma includes [[dopamine]] agonists ([[cabergoline]] or [[bromocriptine]]). | *Medical therapy for prolactinoma includes [[dopamine]] agonists ([[cabergoline]] or [[bromocriptine]]).<ref name="pmid15191331">{{cite journal| author=Liu JK, Couldwell WT| title=Contemporary management of prolactinomas. | journal=Neurosurg Focus | year= 2004 | volume= 16 | issue= 4 | pages= E2 | pmid=15191331 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15191331 }} </ref> | ||
* Preferred regimen: [[Cabergoline]]: 0.25 mg PO twice weekly or 0.5 mg PO once weekly. | **Preferred regimen: [[Cabergoline]]: 0.25 mg PO twice weekly or 0.5 mg PO once weekly. | ||
***The dose may be gradually increased every 4 weeks as needed. | |||
* Alternative regimen: [[Bromocriptine]]: 1.25 mg PO once daily at bedtime for 1 week | ***Maximum dose can be administered up to 1 mg PO twice weekly. | ||
**Alternative regimen: [[Bromocriptine]]: 1.25 mg PO once daily at bedtime for 1 week. | |||
***The dose may be gradually increased every 3 to 7 days as needed and taken in divided doses. | |||
These [[drug]]s reduce the [[tumor]] size and return [[prolactin]] concentration to normal in | *These [[drug]]s reduce the [[tumor]] size in approximately 85% of cases and return [[prolactin]] concentration to normal in more than 90% of patients. | ||
*Both drugs have been approved by the U.S Food and Drug Administration for the treatment of hyperprolactinemia. | |||
===Medical Therapy in pregnancy=== | |||
*[[Bromocriptine]] is considered safe in pregnancy.<ref name="pmid15191331">{{cite journal| author=Liu JK, Couldwell WT| title=Contemporary management of prolactinomas. | journal=Neurosurg Focus | year= 2004 | volume= 16 | issue= 4 | pages= E2 | pmid=15191331 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15191331 }} </ref> | |||
===Indications for withdrawal of Dopamine agonist therapy=== | |||
*Dopamine therapy can be tapered down to lower doses if it fulfills the following criteria:<ref name="pmid15191331">{{cite journal| author=Liu JK, Couldwell WT| title=Contemporary management of prolactinomas. | journal=Neurosurg Focus | year= 2004 | volume= 16 | issue= 4 | pages= E2 | pmid=15191331 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15191331 }} </ref> | |||
**Normal [[prolactin]] level for atleast 2 years. | |||
**Reduction in tumor size by atleast 50%. | |||
**No compression of [[optic chiasm]]. | |||
*Drug cessation can be tried if: | |||
**[[Cavernous sinus]] invasion is not present. | |||
==Radiation Therapy== | ==Radiation Therapy== | ||
Revision as of 20:08, 21 July 2017
|
Prolactinoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Prolactinoma medical therapy On the Web |
|
American Roentgen Ray Society Images of Prolactinoma medical therapy |
|
Risk calculators and risk factors for Prolactinoma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Anmol Pitliya, M.B.B.S. M.D.[2],Faizan Sheraz, M.D. [3]
Overview
Medical therapy for prolactinoma includes dopamine agonists (either Cabergoline or Bromocriptine).
The goal of treatment is to return prolactin secretion to normal, reduce tumor size, correct any visual abnormalities and restore normal pituitary function.[1]
Medical Therapy
- Medical therapy for prolactinoma includes dopamine agonists (cabergoline or bromocriptine).[2]
- Preferred regimen: Cabergoline: 0.25 mg PO twice weekly or 0.5 mg PO once weekly.
- The dose may be gradually increased every 4 weeks as needed.
- Maximum dose can be administered up to 1 mg PO twice weekly.
- Alternative regimen: Bromocriptine: 1.25 mg PO once daily at bedtime for 1 week.
- The dose may be gradually increased every 3 to 7 days as needed and taken in divided doses.
- Preferred regimen: Cabergoline: 0.25 mg PO twice weekly or 0.5 mg PO once weekly.
- These drugs reduce the tumor size in approximately 85% of cases and return prolactin concentration to normal in more than 90% of patients.
- Both drugs have been approved by the U.S Food and Drug Administration for the treatment of hyperprolactinemia.
Medical Therapy in pregnancy
- Bromocriptine is considered safe in pregnancy.[2]
Indications for withdrawal of Dopamine agonist therapy
- Dopamine therapy can be tapered down to lower doses if it fulfills the following criteria:[2]
- Normal prolactin level for atleast 2 years.
- Reduction in tumor size by atleast 50%.
- No compression of optic chiasm.
- Drug cessation can be tried if:
- Cavernous sinus invasion is not present.
Radiation Therapy
Rarely, radiation therapy is used if medical therapy and surgery fail to reduce prolactin concentration. Depending on the size and location of the tumor, radiation is delivered either in low doses over the course of 5 to 6 weeks or in a single high dose. Radiation therapy is effective in approximately 30% of cases.
References
- ↑ Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA; et al. (2011). "Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline". J Clin Endocrinol Metab. 96 (2): 273–88. doi:10.1210/jc.2010-1692. PMID 21296991.
- ↑ 2.0 2.1 2.2 Liu JK, Couldwell WT (2004). "Contemporary management of prolactinomas". Neurosurg Focus. 16 (4): E2. PMID 15191331.